Jubilant Pharmova LtdNSE: JUBLPHARMA
Open the Jubilant Pharmova Ltd page
Follow Jubilant Pharmova LtdFree account. Get a note when Jubilant Pharmova Ltd files.
Q4 FY26 results analysis · May 22, 2026

Jubilant Pharmova Ltd Q4 FY26 Results Analysis: PAT Plunges 68.6%, CDMO Sterile Injectables Surge 46.8%

−21.1%PAT year on year, Rs. 119.30 Cr
Cofacto ResearchPublished May 22, 20262 min readNeutral read
Quick summary

Jubilant Pharmova Ltd's Q4 FY26 numbers came in mixed, with revenue of Rs. 2,290.00 Cr (+18.70% YoY) and PAT growth of -21.10% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateMay 22, 2026
QuarterQ4 FY 2025-2026
Revenue (Q4)Rs. 2,290.00 Cr (+18.70% YoY)
PAT (Q4)Rs. 119.30 Cr (-21.10% YoY)
EBITDA margin15.85% (-267 bps YoY)
EPS (Q4)Rs. 7.55 (-22.30% YoY)
Market capRs. 16,231.89 Cr
CMPRs. 1,018.95

Quarter Snapshot

JUBLPHARMA delivered 18.7% YoY revenue growth in Q4 FY26, led by a 46.8% surge in CDMO Sterile Injectables and a confirmed turnaround in Generics. However, EBITDA margin compressed 267 bps to 15.85%, net debt rose 44.8% to Rs.1,952 Cr, and normalized PAT (excluding exceptional items) declined 68.6% YoY. The company is on track for its Vision 2030 revenue target but faces a stretch to achieve the 23-25% EBITDA margin goal and zero net debt.

Key Investment Insights

Key Positives

  • Revenue grew 18.7% YoY in Q4 FY26 to Rs.22,900 Mn, accelerating from the full-year growth of 14.4%
  • CDMO Sterile Injectables revenue surged 46.8% YoY in Q4, validating the tariff-tailwind thesis
  • Generics segment swung from a loss of Rs.232 Mn in FY25 to a profit of Rs.276 Mn in FY26
  • Allergy Immunotherapy segment posted 41.3% EBIT margin in Q4, the highest among all segments
  • Operating cash flow of Rs.12,268 Mn was 3.09x reported PAT, indicating high earnings quality
  • Net exceptional items were a gain of Rs.592 Mn on a pre-tax basis, mainly from the Salisbury facility sale

Risk Factors

  • EBITDA margin compressed 101 bps YoY (FY26: 16.01% vs FY25: 17.00%), with employee cost and depreciation growing faster than revenue
  • Normalized PAT (excluding exceptional items) declined 68.6% YoY to Rs.3,592 Mn
  • Net Debt increased 44.8% YoY to Rs.19,524 Mn, moving away from the Vision 2030 Zero Net Debt target
  • Radiopharma EBIT margin declined 370 bps YoY to 7.9% in Q4 due to Ruby-Fill supply constraints expected to persist for two more quarters
  • Free cash flow was negative Rs.2,223 Mn for FY26 due to heavy capex of Rs.14,491 Mn
  • Effective tax rate rose to 35.3% in FY26 from 14.7% in FY25, primarily due to the absence of deferred tax credits

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page
Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.